

## TAT peptide

Cat. No.:	HY-P0282
Molecular Formula:	C <sub>65</sub> H <sub>124</sub> N <sub>34</sub> O <sub>15</sub>
Molecular Weight:	1621.91
Sequence:	Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln
Sequence Shortening:	GRKKRRQRRRPQ
Target:	HIV
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### BIOLOGICAL ACTIVITY

<b>Description</b>	TAT peptide is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1 <sup>[1][2]</sup> .
<b>In Vitro</b>	TAT peptide is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1 <sup>[1]</sup> . TAT peptide (GRKKRRQRRRPQ) functionalized hybrid nanoparticles are also studied due to their combined magnetic enrichment and optical detection for cell separation and rapid cell labelling. A cell viability assay reveals good biocompatibility of these hybrid nanoparticles <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Orzáez M, et al. Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment. *Cell Death Dis.* 2012 Oct 25;3:e415.
- [2]. Lou L, et al. Functionalized magnetic-fluorescent hybrid nanoparticles for cell labelling. *Nanoscale.* 2011 May;3(5):2315-23.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA